NASDAQ:ICLR
ICON Public Limited Company (ICLR) Delays Q4/FY 2025 Earnings Release Amid Ongoing Accounting Investigation
Font: Financial Modeling Prep • Feb 25, 2026
ICON Public Limited Company (NASDAQ: ICLR), a leading global contract research organization (CRO), is currently under internal scrutiny for certain accounting practices and controls, primarily related to revenue recognition in fiscal years 2023 through 2025. This has resulted in a delay of its fourth-quarter and full-year 2025 financial results.
On February 12, 2026, ICON announced that it intends to release these results on or prior to April 30, 2026. The company has also withdrawn its previously issued full-year 2025 financial guidance due to the ongoing investigation by the Audit Committee (initiated in late October 2025), supported by outside legal counsel, forensic accountants, and technical experts. Preliminary indications suggest that revenue in 2023 and 2024 may have been overstated by less than 2% for each year, though the full scope remains under review.
The company expects to report one or more material weaknesses in internal control over financial reporting. Prior to the delay announcement, analysts had expected Q4 2025 (ended December 31, 2025) adjusted EPS of approximately $3.27–$3.32 and revenue of around $2.00–$2.01 billion (representing modest year-over-year declines). Full-year 2025 consensus estimates had been in the range of $12.99–$13.03 adjusted EPS and $8.05–$8.11 billion in revenue (down from prior guidance of $8.05–$8.10 billion). These figures are now subject to potential revision once results are released, and the investigation introduces uncertainty.The disclosure triggered a sharp sell-off, with ICLR shares dropping approximately 30–40% (reaching new multi-year lows in the $70–$90 range intraday on February 12) as investors reacted to the delay, guidance withdrawal, and potential restatement risks.
Multiple law firms (e.g., Levi & Korsinsky, Kirby McInerney, Pomerantz, Hagens Berman) have announced investigations into possible securities law violations, and investor alerts have highlighted potential claims for those who purchased shares prior to the news.ICON Public Limited Company (NASDAQ: ICLR) is a prominent player in the CRO industry, providing outsourced clinical development services to pharmaceutical, biotechnology, and medical device companies. It competes with major firms such as IQVIA, Labcorp, Parexel, and Syneos Health. The CRO sector depends heavily on accurate revenue recognition for long-term contracts, making these issues particularly sensitive. Despite the challenges, ICON maintains a relatively conservative balance sheet in many respects. As of the most recent data (trailing metrics around late 2025/early 2026):
- Trailing P/E ratio: approximately 13–20x.
- Price-to-sales ratio: around 1.6–1.9x (down from higher levels before the drop).
- Enterprise value to sales: approximately 1.3–2.0x.
- Enterprise value to operating cash flow: around 9–10x.
- Debt-to-equity ratio: 0.38 (or 38.26%), indicating moderate leverage.
- Current ratio: 1.06, suggesting adequate short-term liquidity to cover obligations.
The investigation and delay underscore risks in financial reporting for CROs amid complex contracts and industry pressures. Investors await the April 2026 release for clarity on restated prior periods, any material weaknesses, updated 2025/2026 outlook, and management's path forward. For the latest updates, refer to ICON's investor relations site or SEC filings.
Market Overview
|
SOXS
Direxion Daily Semiconductor Bear 3X Shares
|
$1.72
8.18%
|
|
NVDA
NVIDIA Corporation
|
$184.89
-5.49%
|
|
ALBT
Avalon GloboCare Corp.
|
$1.09
114.48%
|
|
AEHL
Antelope Enterprise Holdings Limited
|
$1.08
108.90%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
|
$0.46
45.77%
|
|
EOSE
Eos Energy Enterprises, Inc.
|
$6.74
-39.44%
|
|
RXT
Rackspace Technology, Inc.
|
$2.28
68.89%
|
|
NU
Nu Holdings Ltd.
|
$15.06
-9.55%
|
|
TZA
Direxion Daily Small Cap Bear 3X Shares
|
$5.93
-1.33%
|
|
PLUG
Plug Power Inc.
|
$1.91
0.00%
|
